The in vitro fertilization market is projected to attain a valuation of US$ 819.8 million in 2024. It is estimated to witness a CAGR of 9% from 2024 to 2034. The industry is set to reach US$ 1,940.8 million by 2034 on the back of high incidence of infertility.
| Attributes | Details |
|---|---|
| Valuation for 2024 | US$ 819.8 million |
| Valuation for 2034 | US$ 1,940.8 million |
| CAGR from 2024 to 2034 | 9% |
According to the Australian Institute of Health and Welfare 2021’s data, the age of new mothers boosted from 27.9 years in 2009 to 31.9 years in 2019. The age for new moms rising beyond their peak fertility period leads to them facing troubles in conceiving inherently.
Another key influence comes with the advent of fertilization tourism. With the strengthened demand for in vitro fertilization (IVF), many emerging economies like India, Brazil, Mexico, and Ukraine give treatments at a cost-effective product.
For example, the IVF treatment prices in the United States are between US$ 15,000 and 20,000, whereas in India, the cost ranges from US$ 3,000 to US$ 4,000. The cost difference booms the repro tourism. Brazil has experienced an amplification in repro tourism in recent years.
Demand for in vitro fertilization (IVF) services fluctuates from couples to semen and eggs imported. Countries like Greece, the United States, and Russia also employ surrogacy services. This factor flourishes the in vitro fertilization market growth.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Valuation for 2019 | US$ 465.6 million |
| Valuation for 2023 | US$ 1746 million |
| HCAGR from 2019 to 2023 | 9.9% |
From 2019 to 2023, demand for IVF solutions increased at a CAGR of 9.9%. Rising stress levels among couples with the outbreak of the COVID-19 pandemic back in 2019, led to high risks of infertility. It encouraged them to opt for IVF solutions to conceive.
A study published in 2022 by the National Library of Medicine found that the ovary was vulnerable to coronavirus infection. However, neither the COVID-19 infection nor the vaccine had a negative effect on IVF results. Hence, the industry grew at a fast pace in the historical period.
In the forecast period 2024 to 2034, the industry is projected to witness 9% CAGR, a little lesser than the historical CAGR. Growth is anticipated to be pushed by the development of novel technologies, including embryoscope, cryopreservation, laser assisted hatching, and preimplantation genetic screening. High disposable income of millennials has encouraged them to invest in premium healthcare services like the ones mentioned above.
The segmented in vitro fertilization market analysis is encompassed in the ensuing subsection. Based on a comprehensive review, the equipment segment is ruling the product type category. Correspondingly, the fresh non-donor cycle segment is spearheading the cycle category.
| Segment | Equipment |
|---|---|
| Share (2024) | 44.2% |
The equipment sector acquires a significant share through 2034 and aids the ascendency during the forecast period, according to the global in vitro fertilization market. Their amplifying adoption characterizes this during and after IVF therapies.
The innovations in semen analysis techniques and the swift expansion of the embryo incubator market intensify the share of the equipment segment from the forecast period. As clinics seek pre-eminence in patient care and results, the credence of refined equipment is predominant, boosting sales.
The fresh non-donor cycle segment emerges as the segment in the global in vitro fertilization market, accounting for a considerable revenue share through 2034. This segment takes precedence over the others because of its high success rate, better birth rates compared with frozen embryos, and simpler implantation.
The soaring adoption of fresh non-donor cycles, in accordance with the global prevalence of infertility, is an impetus to this segment. The popularity of the fresh non-donor cycle retains its supremacy between 2024 and 2034.
| Segment | Fresh Non-donor Cycle |
|---|---|
| Share (2024) | 38.6% |
The frozen non-donor segment witnessed accelerated growth in the forecast period. This growth is because of higher pregnancy rates from frozen transfers at lower prices. The frozen non-donor cycle segment also imparts better efficiency for patients as well as endocrinologists. The frozen cycle segment stresses less physical and mental health, propelling the growth of this segment in the future.
Principal Consultant
The in vitro fertilization (IVF) industry can be observed in the subsequent tables, which focus on the leading regions in North America, Europe, and Asia Pacific. A comprehensive evaluation demonstrates that Asia Pacific has significant potential for the in vitro fertilization market.
Trend Analysis of In Vitro Fertilization in North America
Technological developments and the appearance of an entrenched healthcare configuration aid the sturdy growth of the in vitro fertilization market
| Countries | CAGR (2024 to 2034) |
|---|---|
| Canada | 11% |
| United States | 8% |
The administrative reform and insurance coverage enhancements are ushering accessibility and encouraging the expansion of IVF adoption in the United States. The changes in societal trends, like late childbirth and spurring infertility rates, propel the demand for in vitro fertilization services in the United States.
The in vitro fertilization market in Canada is indicated by an increased focus on comprehensiveness and accessibility, with endeavors to cater to the imbalance in avenues to fertility therapies. The geographical differences in medical administration and easy usage are obstacles to the distribution chain of in vitro fertilization in Canada.
The promoting realization of fertility preservation alternatives and the escalating consumption of elective egg freezing transforms the demand for the in vitro fertilization (IVF)sector in Canada.
Analytics for IVF Segment in Europe
With a progressive medical structure and superior expertise, Spain lures numerous foreign patients to find demand for in vitro fertilization (IVF) treatment.
| Countries | CAGR (2024 to 2034) |
|---|---|
| Spain | 13.5% |
| Italy | 12 % |
| France | 10.8% |
| United Kingdom | 9.8% |
| Germany | 9% |
The cultural move towards late parenthood boosts a spur in the adoption of IVF services in Spain, demonstrating shifting societal standards. The medical centers in Spain concentrate on tailored care and breakthrough procedures, assisting the reputation as a dominant destination for fertility tourism.
Cultural determinants, like resilient family values and religious impacts, affect the awareness of IVF in Italy, transforming patient choices and treatment methods. Technological innovations and emphasizing on research facilitate demand for in vitro fertilization (IVF)clinics in Italy to remain at the core of innovation, thrusting ongoing advancements in success rates.
The advent of specialized fertility clinics gratifies the shifting requirements of Italian couples, dispensing customized services and complete support.
Government incentives and insurance scope make IVF procurable in France, supporting higher adoption rates and stimulating a compassionate environment for people on fertility therapies. The IVF clinics of France put forward thorough care, assimilating psychological assistance and integral treatments to address the emotional element of infertility. These factors promote the in vitro fertilization market growth in France.
Insights on In Vitro Fertilization Sector in Asia Pacific
Government strategies facilitating reproductive health and soothing the one-child policy advance the adoption of in vitro fertilization techniques in China.
| Countries | CAGR (2024 to 2034) |
|---|---|
| China | 16.8% |
| Japan | 12.5% |
| Australia & New Zealand | 12% |
| India | 9.7% |
The escalating disposable income and shifting way of life encourage the demand for IVF in China. The presence of a wide population base and encouraging medical administration are catalysts promoting the growth of the in vitro fertilization market in China.
Cultural determinants like pressure from society to conceive and the humiliation around infertility thrust couples towards looking at IVF therapies in Japan. The technical innovations and a high standard of medical care infrastructure encourage Japan's position as a spearheading in vitro fertilization market in the Asia Pacific.
Major in vitro fertilization vendors invest in research and development to broaden their product portfolio, which assists the industry growth. The IVF providers are taking an assortment of strategic plans to expand their global presence, with key sector advancements like novel product introduction, partnership agreements, mergers and acquisitions, surged investments, and alliances with other firms.
The in vitro fertilization providers provide economical items to widen and endure in a progressively competitive and escalating market scenario. A primary business approach used by vendors to aid clients and magnify the sector is to produce regionally to curb production prices. The in vitro fertilization market has equipped medicine with some noteworthy advantages during the forecast period.
Key Developments in the In Vitro Fertilization Market
| Date and Approach | Industry Development |
|---|---|
| June 2023, New Product Launch | The launch of United States-based MilliporeSigma's novel CellToxTM Assay Platform was declared. The platform comprises a collection of IVF tests to check the security of products and medicines. |
| May 2023, New Product Launch | WuXi AppTec was introduced in China and its in vitro toxicant abilities were proliferated. Analysis was included as a segment of the expansion and a novel service for making customized in vitro assays is to be declared. |
| April 2023, Acquisition | Thermo Fisher Scientific Inc., based in the United States, acquired CooperSurgical, a dominant IVF provider. This purchase considerably strengthened Thermo Fisher's share in the IVF industry, improving its competition. |
| March 2023, Product Approval | Sweden-based Vitrolife published that it received FDA approval on its Cryotop vitrification equipment. It is an innovative procedure for vitrifying embryos. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market is classified based on equipment, reagents & media, and accessories.
The segment is categorized based on fresh non-donor cycle, frozen non-donor IVF cycle, frozen donor IVF cycle, and fresh donor IVF cycle.
The report consists of key end-users based on fertility clinics, hospitals & surgical centers, and cryobank & research institutes.
The market is classified into conventional IVF, IVF with ICSI, and IVF with donor eggs.
Analysis of the in vitro fertilization market has been carried out in key countries of North America, Latin America, Middle East and Africa, Asia Pacific, and Europe.
Sales are likely to record a valuation of US$ 819.8 million in 2024.
Demand to convert to revenue worth US$ 1,940.8 million by 2034.
The revenue growth exhibits a CAGR of 9% through 2034.
From 2019 to 2023, the sector accelerated at HCAGR of 9.9%.
The equipment sector garners a share of 44.2% in 2024.
The fresh non-donor cycle sector is likely to hold a share of 38.6% in 2024.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Pricing Analysis
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
6.1. Product
6.2. Cycle
6.3. End User
6.4. Type
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
7.1. Equipment
7.2. Reagents and Media
7.3. Accessories
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Cycle
8.1. Fresh Non-donor Cycle
8.2. Frozen Non-donor IVF Cycle
8.3. Frozen Donor IVF Cycle
8.4. Fresh Donor IVF Cycle
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
9.1. Fertility Clinics
9.2. Hospitals & Surgical Centers
9.3. Cryobank and Research Institutes
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
10.1. Conventional IVF
10.2. IVF with ICSI
10.3. IVF with Donor Eggs
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
11.1. North America
11.2. Latin America
11.3. Western Europe
11.4. South Asia
11.5. East Asia
11.6. Eastern Europe
11.7. Middle East & Africa
12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
19. Sales Forecast 2024 to 2034 by Product, Cycle, End User, and Type for 30 Countries
20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
21. Company Profile
21.1. Vitrolife
21.2. Thermo Fisher Scientific Inc
21.3. Cook Group
21.4. IVFtech ApS
21.5. Esco Micro
21.6. Genea Limited
21.7. Fujifilm Irvine Scientific
21.8. The Baker Company
21.9. Kitazato Corporation
Healthcare
March 2023
REP-GB-12785
330 pages
Explore Healthcare Insights
View Reports
In Vitro Fertilization Market
